Meet us at the American Urological Association's Annual Meeting (AUA 2017)
Visit our booth #449 and join us for an oral presentation - abstract 17-1339
Convention Center in Boston, MA,
 May 12-16, 2017 

Join us at the  Meeting of the US and Canadian Academy of Pathology (USCAP 2017)
Visit our booth #708 and learn more about using CellDetect in your laboratory
Henry B. Gonzalez Convention Center in San Antonio, TX, 
March 6-8, 2017 

Meet us at the International Conference of Medical Innovation (MEDinISRAEL 2017)
Visit our booth #D60 to explore potential collaboration

Convention Center, Tel Aviv, Israel, March 7-8, 2017

Join us at the 40th European Congress of Cytology (ECC 2016)
For the presentation of a reproducibility study of CellDetect Bladder - oral abstract 30

Liverpool, UK, Oct 2-5, 2016 

Meet us at the Meeting of the College of American Pathologists (CAP16)
Visit our booth #202 and learn about CellDetect for bladder cancer diagnosis

Wynn/Encore, Las Vegas, NV, Sept 25-28, 2016

Join us at the Meeting of the American Academy of Oral Medicine (AAOM 2016)
For the presentation of the BRONJ risk stratification test - oral abstract OI0732

Atlanta, GA, April 4-9, 2016

Join us at the 31th Congress of the European Association of Urology (EAU 2016)
For the poster presentation of CellDetect for bladder cancer diagnosis - abstract 751

Munich, Germany, March 11-15, 2016 


An extraordinary assembly of Micromedic's shareholders is scheduled on January 3rd, 2017 at 4pm in the Company's offices in Kyriat Atidim

Micromedic announces approval to conduct an extended clinical study with CellDetect on prostate cancer diagnosis

Announcement of an extraordinary assembly of shareholders of Micromedic Technologies

Announcement of the annual general assembly of shareholders of Micromedic Technologies

Micromedic Announces Receipt of Regulatory Approval to Commercialize CellDetect® Bladder Cancer Monitoring Kit in Israel

Micromedic Announces Cooperation with Axella Research for Financing and Execution of Clinical and Regulatory Activities Required for FDA Approval of CellDetect® Bladder Cancer Monitoring

Micromedic Reports Positive Clinical Study Results for Identifying New Genetic Markers to Predict Risk of BRONJ

Micromedic Obtains EU CE Mark for CellDetect® Non-Invasive Test for Detecting Recurrence of Bladder Cancer

Micromedic Reports Successful Clinical Study Results for Monitoring Bladder Cancer Recurrence

Micromedic Reports Successful Interim Results from Bladder Cancer Clinical Study

© Micromedic Technologies Ltd. site mapcontact
Site by Site2goal | Design Studio Michal Lehavi